QPPV.COM KNOWLEDGE ASSESSMENT

Meningococcal Group C Tetanus-Toxoid Conjugate Vaccine: Immunology and Pharmacovigilance

Test your understanding of the concepts covered by Meningococcal Group C Tetanus-Toxoid Conjugate Vaccine: Immunology and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which conclusion is most appropriate when invasive disease is clinically suspected but the serogroup result is unavailable?
Question 2 of 10 Which feature most clearly distinguishes a report of possible immediate hypersensitivity from a routine reactogenicity report?
Question 3 of 10 Which finding would provide the strongest microbiological basis for investigating a suspected MenC breakthrough case?
Question 4 of 10 A seizure occurs several hours after vaccination. Which interpretation is most consistent with the article?
Question 5 of 10 Which combination is most important when assessing suspected MenC vaccine failure?
Question 6 of 10 A report describes invasive meningococcal disease caused by serogroup W in a person previously vaccinated with a MenC conjugate vaccine. What is the most appropriate initial interpretation?
Question 7 of 10 A cluster of unexpected local reactions is reported, but the reports lack lot numbers and co-administered vaccine information. What is the main consequence?
Question 8 of 10 An infant develops fever and irritability after receiving MenC vaccine with several routine vaccines at the same visit. What is the best pharmacovigilance approach?
Question 9 of 10 Why should vaccination dates and age at each dose be collected in a suspected breakthrough investigation?
Question 10 of 10 Why should dose number and schedule context be retained in an adverse-event report involving this vaccine?

Select an answer to continue.

QPPV.com